The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.

Foundation Venture Capital Group (FVCG), the corporate venturing affiliate of New Jersey Health Foundation, has invested $100,000 in Actinobac Biomed.

The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?